A downtrend has been apparent in Phreesia (PHR) lately with too much selling pressure. The stock has declined 18.3% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spott ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 PHREESIA, INC. (Exact name of registrant as specified in its charter) Delaware 20-2275479 (State or oth ...

Financial Data and Key Metrics - Q1 revenue increased by 21% to $101.2 million [16] - Adjusted EBITDA turned positive for the first time in three years, reaching $4.1 million [16] - Average Healthcare Services clients increased by 103 from the prior quarter, with total revenue per AHSC at $24,900 [16] - Operating cash flow for Q1 was just under breakeven at negative $721,000 [20] - Cash position stood at $80 million as of April 30, 2024 [20] Business Line Data and Key Metrics - Payment processing revenue was negatively impacted by $1.7 million due to the accelerated wind-down of a clearinghouse client relationship [17] - The clearinghouse client relationship represented approximately $8 million in annual revenue, impacting fiscal 2025 results [18] - Network solutions are expected to be the primary driver of revenue growth per client, with payments and other products lagging behind [44] Market Data and Key Metrics - The company updated its fiscal 2025 revenue outlook to a range of $416 million to $426 million, reflecting an $8 million reduction due to the clearinghouse client wind-down [19] - Adjusted EBITDA outlook for fiscal 2025 was increased to a range of $21 million to $26 million, reflecting improved operating leverage [20] Company Strategy and Industry Competition - The company is focusing on shorter payback investments to accelerate profitability, driven by internal discounted cash flow analyses and shareholder feedback [22] - Investments in cybersecurity have been ramping up, with continued expectations for increased spending in this area [28] - The company is prioritizing growth while also being more aggressive in driving profitability, considering factors like cost of capital and interest rates [37] Management Commentary on Operating Environment and Future Outlook - Management highlighted the importance of the first quarter as a milestone in the company's journey back to profitability [13] - The company is well-positioned to start generating free cash flow in the second half of fiscal 2025 [21] - The healthcare provider market remains receptive to the company's solutions, with a general view that continuous investment in technology is necessary to drive efficiency and better margins [40] Other Important Information - The company has no borrowings on its revolving credit facility, providing financial flexibility over the next few years [21] - Gross margins reached over 80% in Q1, the highest level in recent history, with expectations to sustain this level through the year [57] Q&A Session Summary Question: Cybersecurity Investments and Financial Impact from Ascension Attack - The company has been increasing investments in cybersecurity for years, with plans to continue ramping up spending in this area [28] - The Ascension cyberattack did not have a significant financial impact on the company, but the industry-wide challenges are unprecedented [26][27] Question: Clearinghouse Client Wind-Down and Risks in the Model - The wind-down of the clearinghouse client relationship was mutually agreed upon due to the client's desire to consolidate vendors, and the process was accelerated by the Change Healthcare cyberattack [32] - No other significant risks related to client contracts or relationships with Change Healthcare were identified [33] Question: Drivers Behind EBITDA Increase and Margin Progression - The strong start to the year and focus on returning to profitability have reinforced the company's commitment to driving profitability more aggressively [37] - The company expects to continue seeing solid operating leverage, contributing to improved EBITDA margins [20] Question: Provider End Market and Phreesia Solution Deployment - The provider end market remains receptive to the company's solutions, with a focus on technology investments to drive efficiency and better margins [40] - The company has continued to win accounts and grow its market share despite industry challenges [40] Question: Strategy for Accelerating Revenue per Client Growth - Network solutions are expected to be the primary driver of revenue growth per client, with payments and other products playing a secondary role [44] Question: MediFind Appointment Requests and New Provider Targeting - The MediFind appointment request product has been well-received, with early traction showing promise for driving value across specialty providers [46] - The company expects MediFind to be a significant driver of network solutions revenue growth in the future [50] Question: Health of Payments Business and Gross Margins - Excluding the impact of the clearinghouse client wind-down, the payments business has been consistent with historical performance [56] - Gross margins reached over 80% in Q1, with expectations to sustain this level through the year [57] Question: Mix and Quality of Healthcare Services Clients - The company continues to add a diverse mix of healthcare services clients, with a focus on shorter payback periods and higher conversion rates [59] Question: Phreesia Launch and Margin Impact - The launch of Phreesia has not had a significant financial impact, as the expenses were already running through the P&L [61] Question: Take Rate Degradation in Payments and Pricing Strategy - The company is comfortable with current pricing levels, with take rates expected to fluctuate around 2.8% in the coming quarters [65] Question: Shorter Payback Investments and Client Upselling - The company is optimizing for profitability and quicker payback periods, with a focus on upselling additional products to clients [67][68]

For the quarter ended April 2024, Phreesia (PHR) reported revenue of $101.22 million, up 20.7% over the same period last year. EPS came in at -$0.35, compared to -$0.70 in the year-ago quarter. The reported revenue represents a surprise of +0.20% over the Zacks Consensus Estimate of $101.01 million. With the consensus EPS estimate being -$0.51, the EPS surprise was +31.37%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

Phreesia (PHR) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.70 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 31.37%. A quarter ago, it was expected that this developer of health care software would post a loss of $0.58 per share when it actually produced a loss of $0.56, delivering a surprise of 3.45%. Over the last four quarters, the c ...

Exhibit 99.1 Phreesia Announces First Quarter Fiscal 2025 Results ALL-REMOTE COMPANY/WILMINGTON, D.E., May 30, 2024 – Phreesia, Inc. (NYSE: PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal first quarter ended April 30, 2024. "I am tremendously proud of our team's commitment to our growth and profitability objectives." said CEO and Co- Founder Chaim Indig. 1 Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q1 Fiscal Year 2025 Sta ...

The average prediction of analysts places 'Revenus- Network solutions' at $26.04 million. The estimate indicates a change of +20% from the prior-year quarter. The collective assessment of analysts points to an estimated 'Revenus- Payment processing fees' of $27.92 million. The estimate indicates a change of +15.1% from the prior-year quarter. Wall Street analysts expect Phreesia (PHR) to post quarterly loss of $0.51 per share in its upcoming report, which indicates a year-over-year increase of 27.1%. Revenu ...

andreswd Summary Following my coverage of Phreesia (NYSE:PHR), for which I reiterated a buy rating given that fundamentals remained sound and that PHR could continue to see pricing tailwinds ahead, this post is to provide an update on my thoughts on the business and stock. I reiterate my buy rating for PHR as I see the business continuing to grow revenue at 20+% and the adjusted EBITDA margin inflecting upwards as the business scales. The new product rolled out to target post-script engagements should also ...

Phreesia (PHR) reported $95.01 million in revenue for the quarter ended January 2024, representing a year-over-year increase of 24%. EPS of -$0.56 for the same period compares to -$0.72 a year ago.The reported revenue represents a surprise of +2.01% over the Zacks Consensus Estimate of $93.13 million. With the consensus EPS estimate being -$0.58, the EPS surprise was +3.45%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

Phreesia (PHR) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.45%. A quarter ago, it was expected that this developer of health care software would post a loss of $0.72 per share when it actually produced a loss of $0.58, delivering a surprise of 19.44%.Over the last four quarters, the com ...